 AUSTIN, Texas, June 16, 2021 GLOBE NEWSWIRE -- Plus Therapeutics, Inc. Nasdaq: PSTV the Company, a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that the Data and Safety Monitoring Board recommended the Company proceed to the eighth cohort of the Phase 1 dose escalation ReSPECTTM trial, which is evaluating the Companys lead investigational drug, Rhenium NanoLiposome RNLTM, in patients with recurrent glioblastoma GBM. 